AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 182 min read$CMND

HRT FINANCIAL LP sold $73K of CMND

HRT FINANCIAL LP sold 22,139 shares of Clearmind Medicine Inc. (CMND) at $3.31 on 2026-06-16.

Original reporting
SEC EDGAR · HRT FINANCIAL LP
Published Jun 18, 2026, 9:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 18, 2026, 9:08 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$CMND
Bearish
medium confidence
Mentioned
$CMND
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CMNDBearishLow
01

Why it matters

A disclosed open-market sale by a 10% owner can influence microcap sentiment and short-term order flow, but it does not provide new operating, regulatory, or financial guidance.

02

Market read

Traders may treat this as a modest negative sentiment datapoint for CMND, mainly relevant for positioning around liquidity and ownership signals.

03

What to watch

The filing does not disclose intent; traders should watch for subsequent Form 4s from the same holder and compare total remaining ownership (81,353 shares after sale) versus prior filings.

Relevance 3/10Novelty 5/10Timing: Filed 2026-06-18 after-hours; reflects sale executed 2026-06-16.

Background

The article is an SEC Form 4 insider transaction disclosure for Clearmind Medicine Inc. (CMND).

Company-level read

Ticker impact

$CMNDBearishMedium confidence
Context

HRT Financial LP, a 10% owner, filed a Form 4 showing an open-market sale of 22,139 CMND shares at $3.3060 on 2026-06-16.

Expected impact

Likely limited, short-lived sentiment pressure; any move would be small unless follow-on selling is disclosed.

Evidence & confidence

The filing is primary-source (Form 4) and quantifies the sale size and price, but it lacks a stated reason and is not a company operational update.

Market effects

Sector

No clear sector read-through; this is company-specific ownership activity.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

A 10b5-1 plan is not used here, but sales can be routine liquidity/portfolio rebalancing rather than a bearish view on the business.

Key entities

  • issuer
    Clearmind Medicine Inc.

    Subject of the Form 4 insider transaction; ticker CMND.

  • 10% owner
    HRT Financial LP

    Reporter/large holder executing the open-market sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CMND insider trading history →

Related articles

SEP 1
$CMNDMedAI 8/10

Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled

Clearmind Medicine (CMND) has started Phase IIa of its trial for CMND-100, a treatment for Alcohol Use Disorder, with six patients enrolled. The trial is evaluating safety, tolerability, and preliminary efficacy. The company reported positive data from earlier trial phases, supporting continued development. CMND-100 is Clearmind's lead investigational psychedelic-based therapeutic.

sina.com.hk2 min
AUG 13
$CMNDMed

Clearmind Medicine Inc.: Clearmind Advances CMND-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint

Clearmind Medicine (Nasdaq: CMND) said its independent DSMB approved advancing its FDA-regulated Phase I/II trial of CMND-100 for alcohol use disorder from Part A to Parts B and C. Part A met the primary safety endpoint in healthy participants. Part B will test 80 mg and 160 mg in AUD patients; Part C will test 160 mg in healthy participants.

finanznachrichten.de4 min
AUG 7
$MRNAMed

Weekly Buzz: MRNA, NVS, SNY Gain Approvals; EBS, LSTA Cut Jobs; TARS, BIVI Drive Deals & Data

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.

rttnews.com7 min
MAY 29
$CMNDMedAI 9/10

Clearmind Medicine Shares Jump 47% After Japan Patent Filing For Depression Treatment

Clearmind Medicine Inc. (CMND) shares rose 46.72% to $3.59 on Friday after the company said a Japanese patent application was published covering compositions using 5-Methoxy-2-aminoindan (MEAI) for depression treatment. The filing, the company said, adds to its intellectual property portfolio for non-hallucinogenic neuroplastogen-derived therapeutics. Volume was 41.05 million shares versus 612,955 average.

rttnews.com3 min